MYC and cancer: As MYC is known to be deregulated in 30–50% of human malignancies with poor prognosis, our novel discovery may have significant implication for cancer therapy: targeting both Menin and MYC pathways might potentially work for human malignancies with aberrant expression of both MYC and Menin.